Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Pointing to increases in AstraZeneca’s research and development budget under Soriot, the successful launch of many blockbuster drugs and the expansion of the business into rare diseases, vaccines and immunology...
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...The results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions....
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...Over the past year or so, the rapid development of artificial intelligence has sparked trepidation over how it may disrupt various facets of the modern world — from job security to the development of new...
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...The National Institute for Health and Care Excellence announced on Tuesday that it would not approve the medication Enhertu, developed by pharmaceutical companies Daiichi Sankyo and AstraZeneca, to treat...
Breakthrough medicine will now be subject to further review by committee of independent experts
...Meanwhile, a trial is looking at whether metformin, commonly prescribed for type 2 diabetes, might delay the development of other chronic diseases....
...It is a similar milestone-based structure to many partnerships in the pharmaceutical industry....
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
International Edition